menu
    • menu
    [{"orgOrder":0,"company":"CRISPR Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Exagamglogene Autotemcel","moa":"BCL11A","graph1":"Hematology","graph2":"Phase I\/ Phase II","graph3":"CRISPR Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CRISPR Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"CRISPR Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Hemab Therapeutics","sponsor":"Deep Track Capital","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"DENMARK","productType":"Antibody","year":"2023","type":"Series B Financing","leadProduct":"HMB-001","moa":"Factor VIIa","graph1":"Hematology","graph2":"Phase I\/ Phase II","graph3":"Hemab Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Hemab Therapeutics \/ Deep Track Capital","highestDevelopmentStatusID":"7","companyTruncated":"Hemab Therapeutics \/ Deep Track Capital"},{"orgOrder":0,"company":"AbFero Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"SP-420","moa":"Iron","graph1":"Hematology","graph2":"Phase I\/ Phase II","graph3":"AbFero Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AbFero Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"AbFero Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Jubilant Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"JBI-802","moa":"LSD1\/HDAC6","graph1":"Hematology","graph2":"Phase I\/ Phase II","graph3":"Jubilant Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Jubilant Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Jubilant Therapeutics \/ Inapplicable"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Jubilant Therapeutics

                            U.S.A arrow
                            Iran Expo
                            Not Confirmed

                            Jubilant Therapeutics

                            U.S.A arrow
                            Iran Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : JBI-802

                            Therapeutic Area : Hematology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            JBI-802 Phase I Data Suggests Potential in Immunotherapy-Resistant Tumors

                            Details : JBI-802 is a first-in-class CoREST inhibitor with dual action on LSD1 and HDAC6, undergoing phase 1/2 trials for essential thrombocythemia and related neoplasms.

                            Product Name : JBI-802

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            August 01, 2024

                            Lead Product(s) : JBI-802

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Hemab Therapeutics

                            Denmark arrow
                            Iran Expo
                            Not Confirmed

                            Hemab Therapeutics

                            Denmark arrow
                            Iran Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HMB-001

                            Therapeutic Area : Hematology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Deep Track Capital

                            Deal Size : $135.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Hemab Therapeutics Announces $135M Series B Financing to Advance First Prophylactic Treatments for Underserved...

                            Details : The Funding enables completion of ongoing Phase 1/2 study of bispecific antibody HMB-001 in Glanzmann Thrombasthenia, initiation of pivotal studies, start and conclusion of Phase 1/2 study of HMB-VWF in von Willebrand Disease, as well as future pipeline ...

                            Product Name : HMB-001

                            Product Type : Antibody

                            Upfront Cash : Undisclosed

                            February 20, 2023

                            Lead Product(s) : HMB-001

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Deep Track Capital

                            Deal Size : $135.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            CRISPR Therapeutics

                            U.S.A arrow
                            Iran Expo
                            Not Confirmed

                            CRISPR Therapeutics

                            U.S.A arrow
                            Iran Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Exagamglogene Autotemcel

                            Therapeutic Area : Hematology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            FDA offers CRISPR, Vertex drug program VIP status for its comeback play

                            Details : CTX001 has received Orphan Drug Designation from the U.S. FDA for transfusion-dependent beta thalassemia and from the EMA for sickle cell disease and transfusion-dependent beta thalassemia .

                            Product Name : CTX001

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            November 05, 2020

                            Lead Product(s) : Exagamglogene Autotemcel

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            AbFero Pharmaceuticals

                            U.S.A arrow
                            Iran Expo
                            Not Confirmed

                            AbFero Pharmaceuticals

                            U.S.A arrow
                            Iran Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SP-420

                            Therapeutic Area : Hematology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Abfero Announces PK Study Results For SP-420 in Transfusional Iron Overload -- Proceeds With PHASE 1-2 Trial O...

                            Details : The PK data confirmed that the doses of SP-420 planned for the company's upcoming Phase 1-2 trial in patients with transfusional iron overload (TIO) should provide sufficient drug exposure for the desired therapeutic effect.

                            Product Name : SP-420

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            June 10, 2020

                            Lead Product(s) : SP-420

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth